



Oregon Prescription Drug Affordability Board Regular Meeting
Wednesday, February 18, 2026
Minutes approved by the board on March 18, 2026

Web link to the meeting video: <https://youtu.be/LIUdgtiA4Mw>

Web link to the meeting materials: <https://dfr.oregon.gov/pdab/Documents/20260218-PDAB-document-package.pdf>

Call to order: Acting Chair Dan Hartung called the meeting to order at 8:04 a.m.

Roll call:

Present: Acting Chair Dan Hartung, Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman

Absent: Chair Shelley Bailey, John Murray

Board declarations of conflict of interest and meetings with entities or individuals related to board activities: There were no board declarations. View at video minute [00:01:32](#).

Approval of board minutes: Acting Chair Hartung approved by consensus the Jan. 21, 2026, minutes as shown on [Pages 2-10](#) of the agenda materials. View at video minute [00:02:20](#).

PDAB program update: Sarah Young, Oregon PDAB executive director, provided a program update. View the video at minute [00:03:13](#).

General public comment: Public comment was received from the following individuals who signed up in advance: Dharia McGrew, PhRMA; Primo Castro, Biotechnology Innovation Organization; John Mullin, Oregon Coalition for Affordable Prescriptions; Mary Anne Cooper, Regence; Lorren Sandt, Caring Ambassadors; and Charlie Fisher, OSPIRG. The board received 11 written comments, which are posted on the [PDAB website](#). View at video minute [00:10:57](#).

Executive session: The board adjourned to executive session for legal advice pursuant to ORS 192.660(2)(f). No decisions were made in executive session. The board returned to open session and roll was called to determine a quorum.

Roll call:

Present: Acting Chair Dan Hartung, Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman

Absent: Chair Shelley Bailey, John Murray

Annual policy review: The board reviewed and voted on the amended PDAB Policies and Procedures 1. View the revisions on [Pages 11-16](#) of the agenda materials. The amended [Policies and Procedures 1 document](#) has been posted on the PDAB website. View the discussion and vote at video minute [00:33:53](#).



MOTION to accept the revisions to our policy (Policies and Procedures 01) as amended.

Board Vote:

Motion: Dan Kennedy

Second: Michele Koder

Yes: Lauri Hoagland, Dan Kennedy, Michele Koder, Chris Laman, Acting Chair Dan Hartung

No: None

Absent: Chair Shelley Bailey, John Murray

MOTION PASSED 5-0

House Bill 4040 (2026): Section 38-39: The board discussed Sections 38-39, which relate to Oregon PDAB, in House Bill (2026), a proposed health care reformed bill. Amendment 14 would provide additional language in ORS 646A.694 that PDAB may identify at least one insulin product from the provided lists under review. Read the PowerPoint slides on [Pages 17-19](#) in the agenda materials. View at video minute [00:41:11](#).

Policy recommendations to include in the 2025 drug review report: The board discussed policy recommendations for including in the 2025 drug review report, which will be submitted to the Oregon Legislature in March. The board will vote on both the recommendations and final drug review report at the March meeting. Read the recommendations on [Pages 20-23](#) and the draft drug review report on [Pages 27-38](#) of the agenda materials. View at video minute [00:57:55](#).

2026 drug review: The board discussed the updated preliminary lists of prescription drugs and insulin products for the 2026 drug review, based on commercial insurer reporting from calendar year 2024. The [data dashboard and preliminary list](#) of drugs are posted on the PDAB website. View at video minute [02:02:15](#).

Announcements: Acting Chair Hartung announced the next board meeting will be March 18, 2026 at 8 a.m. View at video minute [03:09:40](#).

Adjournment: Acting Chair Hartung adjourned the meeting at 11:49 a.m. with all board members in agreement. View at video minute [03:09:47](#).